MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $19.90 (194.38% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Robert W. BairdInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016WedbushReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Jefferies GroupDowngradeBuy -> Hold$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016Raymond JamesInitiated CoverageOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Canaccord GenuityReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Bank of AmericaDowngradeNeutral -> Underperform$26.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015FBR & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015OppenheimerReiterated RatingOutperform$53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Barrington ResearchInitiated CoverageBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($0.74)($0.75)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.82)($0.81)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.87)($0.85)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.77)($0.92)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.75)($0.74)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.66)($0.79)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.52)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.50)($1.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.47)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.79)($0.73)($0.75)
Q2 20163($0.76)($0.73)($0.74)
Q3 20163($0.75)($0.75)($0.75)
Q4 20163($0.76)($0.75)($0.76)
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.55)($0.55)($0.55)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)
Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
DateHeadline
06/25/16 08:41 AMStrong Sell Calls Recommendations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 0 - Investor Newswire
06/23/16 05:16 PMKaryopharm Therapeutics : Initiates Phase 1 Clinical Trial with KPT-9274
06/23/16 05:16 PMKaryopharm Therapeutics (KPTI) Commences KPT-9274 Phase 1 in Adv. Solid Malignancies or NHL
06/22/16 09:31 AMKaryopharm Therapeutics (KPTI) Commences KPT-9274 Phase 1 in Adv. Solid Malignancies or NHL - StreetInsider.com
06/22/16 09:26 AMKaryopharm Commences First Stage Clinical Study With KPT-9274 -
06/22/16 06:39 AMKaryopharm Initiates Phase 1 Clinical Trial with KPT-9274 - [at noodls] - NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial ...
06/18/16 04:17 PMStrong Buy Calls Count For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 3 - Investor Newswire
06/17/16 04:45 PMKaryopharm Therapeutics : Outlines Key Selinexor Clinical Development Achievements
06/17/16 03:08 PMKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 07:39 AMKaryopharm Outlines Key Selinexor Clinical Development Achievements - [at noodls] - - Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma - - Patient Dosing Underway in Phase 1b Clinical Trial of Selinexor in Combination with Chemotherapeutic, Targeted and Immunotherapeutic ...
06/15/16 06:49 AMKaryopharm to Present at the 2016 JMP Securities Life Science Conference - [at noodls] - NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive ...
06/13/16 07:30 AMKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : June 13, 2016 -
06/10/16 05:04 PMCompany Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc Presents Preliminary STOMP Phase 1b Clinical Data ... - Smarter Analyst
06/10/16 07:43 AMKaryopharm Therapeutics (KPTI) Announces Poster Presentation of Updated KPT-330 Phase 1b Data - StreetInsider.com
06/10/16 06:39 AMKaryopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting - [at noodls] - - Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma - - Preclinical Data for Second-Generation ...
06/08/16 05:11 PMKARYOPHARM THERAPEUTICS INC. (NASDAQ:KPTI) Financial Condition Compared to S&P 500 - CML News
06/08/16 07:40 AMKaryopharm Therapeutics Inc. (KPTI) is Trading Higher on Unusual Volume for June 06 - Equities.com
06/07/16 07:27 AMChione Ltd, 10% Owner of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sells 17,855 shares
06/06/16 08:36 AMRaymond James Initiates Coverage on Karyopharm Therapeutics Inc to Outperform - Trade Calls
06/04/16 07:40 AMChione Ltd, 10% Owner of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sells 40,000 shares
06/02/16 05:09 PMKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Update & Estimates - Stock Tick Tock - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to post earnings of $-0.75 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 07:43 AMKaryopharm Therapeutics Inc (KPTI) Lowered to Hold at Jefferies Group - Let Me Know About This - Karyopharm Therapeutics Inc (KPTI) Lowered to Hold at Jefferies GroupLet Me Know About ThisKaryopharm Therapeutics logo Karyopharm Therapeutics Inc (NASDAQ:KPTI) was downgraded by equities researchers at Jefferies Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, ...A Major Shareholder at Karyopharm Therapeutics (NASDAQ: KPTI) is Selling SharesAnalyst Ratingsall 4 news articles »
06/01/16 07:40 AMKaryopharm Therapeutics Inc (KPTI) is Trading Higher on Unusual Volume for May 30 - Equities.com - Karyopharm Therapeutics Inc (KPTI) is Trading Higher on Unusual Volume for May 30Equities.comKaryopharm Therapeutics Inc (KPTI) experienced unusually high volume on May. 30, as the stock gained 0.94% to a closing price of $9.62. The stock saw 333,672 shares trade hands over the course of the day on 2,198 trades. Given that the stock's average ...and more »
06/01/16 07:03 AMKaryopharm to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - NEWTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, ...
05/31/16 05:03 PMNews Sentiment For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Investor Newswire - News Sentiment For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Investor NewswireKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Average broker stands at 2 while it was 2 three months ago. The quarterly report of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) can be made public close to 2016-08-08. It is estimated by the recent update ...and more »
05/31/16 09:05 AMStock Review and Earnings Check on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - HNN - Stock Review and Earnings Check on Karyopharm Therapeutics Inc. (NASDAQ:KPTI)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report quarterly EPS of $-0.71. The company's next earnings report is expected to be ...and more »
05/27/16 07:34 PMRaymond James Initiates Coverage on Karyopharm Therapeutics Inc. (KPTI) By Announcing An Initial Rating Of “Outperform” - Karyopharm Therapeutics Inc. (NASDAQ:KPTI). On March 15 Jefferies maintained a company rating of “Hold” and lowered the price expectation to $10.00 from $14.00. Equity analyst Bank of America downgraded the stock and lowered the price target on March ...
05/27/16 07:21 AMCoverage initiated on Karyopharm Therapeutics by Raymond James -
05/25/16 06:56 PMKaryopharm Therapeutics Inc Can't Burn Your Long Portfolio. Has Another Strong Session - Wall Street Hints and News - Karyopharm Therapeutics Inc Can't Burn Your Long Portfolio. Has Another Strong SessionWall Street Hints and NewsThe stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! The stock increased 8.39% or $0.73 during the last trading session, hitting $9.43. About 166,481 shares traded hands. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has ...
05/25/16 07:40 AMKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : KPTI-US : May 25, 2016 -
05/25/16 12:32 AMChione Ltd, 10% Owner of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sells 20,000 shares - According to Karyopharm Therapeutics Inc's most recent Form 4 filing with the SEC dated May 23 08:16 PM, company 10% Owner, Chione Ltd disclosed selling 20,000 shares at a cost of $8.18. At the time of this transaction (May 19), this trade was worth $ ...
05/24/16 07:14 PMEarnings Review and Stock Rundown for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Wall Street Hints and News - Earnings Review and Stock Rundown for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Karyopharm Therapeutics Inc. (NASDAQ:KPTI ...and more »
05/21/16 12:07 AMChione Ltd, 10% Owner of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sells 30,000 shares - According to Karyopharm Therapeutics Inc's most recent Form 4 filing with the SEC dated May 19 08:54 PM, company 10% Owner, Chione Ltd disclosed selling 30,000 shares at a cost of $8.15. At the time of this transaction (May 18), this trade was worth $ ...
05/19/16 07:32 AMKaryopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting - [at noodls] - NEWTON, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary activity of ...
05/18/16 05:12 PMKaryopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting - [at noodls] - NEWTON, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor (KPT-330), ...
05/18/16 04:46 PM5:46 pm Karyopharm Therapeutics to present 3 abstracts involving selinexor at ASCO -
05/18/16 11:28 AMRevenue Update on Karyopharm Therapeutics Inc(NASDAQ:KPTI) - Trade Calls - Revenue Update on Karyopharm Therapeutics Inc(NASDAQ:KPTI)Trade CallsKaryopharm Therapeutics Inc(NASDAQ:KPTI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Company reported revenue of $0.00. Analysts estimated a revenue of $50.00K. Earnings per ...Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Analyst ReviewRisers & FallersKaryopharm Therapeutics Incorporated (NASDAQ:KPTI) Shorted Shares Decreased By 13.8%Franklin Independentall 6 news articles »
05/14/16 12:39 AMKaryopharm Therapeutics Inc (KPTI) Stock Price Down 0.1% Following Weak Earnings - (KPTI) on Monday reported a loss of $27.1 million in its first quarter. Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) were down 0.1% during mid-day trading on Tuesday following a weaker than expected earnings announcement, MarketBeat.com reports.
05/12/16 01:08 AMKaryopharm Therapeutics Inc (KPTI) to Post Q1 2017 Earnings of ($0.57) Per Share, Wedbush Forecasts - Washington News Wire - Washington News WireKaryopharm Therapeutics Inc (KPTI) to Post Q1 2017 Earnings of ($0.57) Per Share, Wedbush ForecastsWashington News WireKaryopharm Therapeutics logo Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Equities research analysts at Wedbush issued their Q1 2017 EPS estimates for shares of Karyopharm Therapeutics in a note issued to investors on Monday, according to Zacks ...
05/11/16 07:50 PMConsensus Rating Review for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - B.O.D.Y Confidential - Consensus Rating Review for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1.5 on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/11/16 12:53 AMKaryopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress - NEWTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2016 and commented on recent accomplishments and clinical ...
05/10/16 07:36 PMSmall Cap Volatile Stocks: Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), California Resources Corporation (NYSE ... - KC Register - Small Cap Volatile Stocks: Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), California Resources Corporation (NYSE ...KC RegisterKaryopharm Therapeutics, Inc. (NASDAQ:KPTI) reported financial results for the first quarter 2016. For the quarter ended March 31, 2016, research and development expense was $21.8 million compared to $20.8 million for the quarter ended March 31, 2015.and more »
05/09/16 05:04 PMEdited Transcript of KPTI earnings conference call or presentation 9-May-16 12:30pm GMT -
05/09/16 06:47 AMKaryopharm Therapeutics posts 1Q loss -
05/09/16 06:37 AMKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/09/16 06:36 AMKaryopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress - [at noodls] - Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma First-in-Human Study Initiated with Second-Generation SINE™ Compound KPT-8602 in Multiple Myeloma Phase 2 Clinical Data ...
05/09/16 06:07 AMQ1 2016 Karyopharm Therapeutics Inc Earnings Release - Before Market Open -
05/08/16 09:18 PMNext Weeks Broker Price Targets For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Share Trading News - Next Weeks Broker Price Targets For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Share Trading News03/16/2016 – Karyopharm Therapeutics Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 16 price target on the stock. 03/15/2016 – Karyopharm Therapeutics Inc. was downgraded to “underperform” by analysts at Bank ...and more »
03/23/16 02:25 PMETF’s with exposure to Karyopharm Therapeutics, Inc. : March 23, 2016 -
03/21/16 01:04 PMKaryopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: Q4, 2015 By the Numbers -
About Karyopharm Therapeutics

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KPTI
  • CUSIP:
Key Metrics:
  • Previous Close: $6.76
  • 50 Day Moving Average: $8.53
  • 200 Day Moving Average: $8.79
  • P/E Ratio: N/A
  • P/E Growth: 0.19
  • Market Cap: $243.09M
  • Current Quarter EPS Consensus Estimate: $-3.07 EPS
Additional Links:
Karyopharm Therapeutics (NASDAQ:KPTI) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha